Prospective trial examining safety and biological effects of combining Ipilimumab and radiotherapy in patients with metastatic melanoma.

Trial Profile

Prospective trial examining safety and biological effects of combining Ipilimumab and radiotherapy in patients with metastatic melanoma.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms RT and Ipi in Mestatstatic Melanoma
  • Most Recent Events

    • 04 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top